The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1
Open accessAbstract
Diabetic cardiomyopathy is a common complication in patients with diabetes and is associated with underlying chronic inflammation and cardiac cell death, subsequently leading to heart failure (HF). ELAV-like protein 1 (ELAVL1) plays a critical role in the progression of inflammation and HF. However the role of ELAVL-1 in inflammation induced cardiac cell death (pyroptosis) under hyper glycemic condition remains elusive. Our data demonstrates that ELAVL1 expression augmented with a concomitant increase in caspase-1 and IL-1 beta expression in human hearts and human ventricular cardiomyocytes under hyperglycemic condition. Furthermore, ELAVL1 knockdown abrogates TNF-α induced canonical pyroptosis via NLRP3, caspase-1 and IL-1beta suppression. Bioinformatics analysis and target validation assays showed that miR-9 directly targets ELAVL1. Interestingly, miRNA-9 expression significantly reduced in high glucose treated cardiomyocytes and in human diabetic hearts. Inhibition of miR-9 upregulates ELAVL1 expression and activates caspase-1. Alternatively, treatment with miR-9 mimics attenuates hyperglycemia-induced ELAVL1 and inhibits cardiomyocyte pyroptosis. Taken together our study highlights the potential therapeutic implications of targeting miR-9/ELAVL1 in preventing cardiomyocyte cell loss during HF in diabetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., & Nuñez, G. (2009) · Nature Immunology · doi:10.1038/ni.1703 · Cited by 1,834
Cited by
Role of pyroptosis in inflammation and cancer
Wei, X., Xie, F., Zhou, X., Wu, Y., Yan, H., Liu, T., Huang, J., Wang, F., Zhou, F., & Zhang, L. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00905-x · Cited by 699
Role of pyroptosis in cardiovascular disease
Zhaolin, Z., Guohua, L., Shiyuan, W., & Zuo, W. (2019) · Cell Proliferation · doi:10.1111/cpr.12563 · Cited by 493
Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications
Zeng, C., Wang, R., & Tan, H. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33568 · Cited by 283
Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy
Yang, F., Qin, Y., Lv, J., Wang, Y., Che, H., Chen, X., Jiang, Y., Li, A., Sun, X., Yue, E., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1029-4 · Cited by 273
Role of pyroptosis in cardiovascular diseases
Jia, C., Chen, H., Zhang, J., Zhou, K., Zhuge, Y., Niu, C., Qiu, J., Rong, X., Shi, Z., Xiao, J., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.028 · Cited by 267
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
RNA-Binding Proteins Hold Key Roles in Function, Dysfunction, and Disease
Kelaini, S., Chan, C., Cornelius, V. A., & Margariti, A. (2021) · Biology · doi:10.3390/biology10050366 · Cited by 94
Metadata
- Authors
- Jeyabal, P., Thandavarayan, R. A., Joladarashi, D., Suresh Babu, S., Krishnamurthy, S., Bhimaraj, A., Youker, K. A., Kishore, R., & Krishnamurthy, P.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 471
- Issue
- 4
- Pages
- 423-429
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2275022502
- Cited by
- 169
- References
- 1
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.